Compare PM & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PM | NVS |
|---|---|---|
| Founded | 1987 | 1895 |
| Country | United States | Switzerland |
| Employees | N/A | 75267 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.9B | 286.9B |
| IPO Year | 2007 | N/A |
| Metric | PM | NVS |
|---|---|---|
| Price | $160.81 | $147.89 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 5 |
| Target Price | ★ $189.78 | $144.00 |
| AVG Volume (30 Days) | ★ 4.0M | 1.3M |
| Earning Date | 04-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 3.84% | 2.08% |
| EPS Growth | ★ 60.62 | N/A |
| EPS | ★ 7.26 | N/A |
| Revenue | ★ $40,648,000,000.00 | N/A |
| Revenue This Year | $10.54 | $2.30 |
| Revenue Next Year | $6.65 | $5.27 |
| P/E Ratio | ★ $21.22 | $23.13 |
| Revenue Growth | ★ 7.31 | N/A |
| 52 Week Low | $142.11 | $108.53 |
| 52 Week High | $191.30 | $170.46 |
| Indicator | PM | NVS |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 39.23 |
| Support Level | $160.03 | $145.30 |
| Resistance Level | $162.48 | $157.63 |
| Average True Range (ATR) | 3.71 | 1.94 |
| MACD | 0.39 | -0.31 |
| Stochastic Oscillator | 82.25 | 1.03 |
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets. It also owns the Veev brand in vapes.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.